Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + fludarabine + cyclosporin + alemtuzumab + GM-CSF
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This is a multi-agent combination regimen consisting of five drugs: cyclophosphamide, fludarabine, cyclosporin, alemtuzumab (also known as CAMPATH-1H), and granulocyte-macrophage colony-stimulating factor (GM-CSF). Cyclophosphamide is an alkylating agent that interferes with DNA replication. Fludarabine is a purine analog that inhibits DNA synthesis. Cyclosporin is an immunosuppressant that inhibits calcineurin and T-cell activation. Alemtuzumab is a monoclonal antibody targeting CD52 on lymphocytes, leading to cell lysis. GM-CSF stimulates the production of white blood cells and enhances immune function. This combination has been studied in the context of hematopoietic stem cell transplantation conditioning regimens and for certain hematologic malignancies[4][8].
- Other names
- cytophosphane
02
Targets
CD52 (CD52 Antigen)CN (Calcineurin)PPIA (Peptidyl-prolyl cis-trans isomerase A)DNAPOLA1 (DNA polymerase alpha)POLD1 (DNA polymerase delta)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on cyclophosphamide + fludarabine + cyclosporin + alemtuzumab + GM-CSF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + fludarabine + cyclosporin + alemtuzumab + GM-CSF.